Consensus Amgen Inc. Sao Paulo

Stocks

AMGN34

BRAMGNBDR004

Pharmaceuticals

Market Closed - Sao Paulo 15:38:31 2026-10-13 EDT			5-day change	1st Jan Change
74.40 ^BRL	-7.81%		+3.69%	+12.80%

10-13	Goldman Sachs Adjusts Price Target on Amgen to $475 From $450	MT
10-12	Amgen's Q3 Results Should Reflect Continued Commercial Momentum, BofA Securities Says	MT

815d3bc92033aee795dd3a853c8.-uNWlfKCxA_faFN15Je9hYBX4DqF7sPncb-7IgymG9U.jbEgp7XrpXWQIwA9p6fJtbkbqnO3m_qxM4-IG3mQerGLkBLxnLGvXokfHg~4722f7eb1899f8f768fabd9c8b744651

Analysts' recommendations: Amgen Inc.

10-13	Goldman Sachs Adjusts Price Target on Amgen to $475 From $450	MT
10-12	Amgen's Q3 Results Should Reflect Continued Commercial Momentum, BofA Securities Says	MT
10-12	BofA Securities Adjusts Amgen Price Target to $328 From $317, Maintains Underperform Rating	MT
10-12	Wells Fargo Adjusts Price Target on Amgen to $430 From $435	MT
10-12	BMO Capital Adjusts Price Target on Amgen to $415 From $450	MT
10-09	UBS Adjusts Price Target on Amgen to $470 From $430, Maintains Buy Rating	MT
10-08	RBC Raises Price Target on Amgen to $430 From $400, Keeps Outperform Rating	MT
10-07	Morgan Stanley Adjusts Price Target on Amgen to $359 From $362	MT
09-28	Scotiabank Raises Amgen Price Target to $500 From $450, Sector Outperform Rating Kept	MT
09-23	Jefferies Adjusts Amgen Price Target to $410 From $367, Maintains Hold Rating	MT
09-10	HSBC Downgrades Amgen to Hold From Buy, Adjusts Price Target to $425 From $445	MT
09-08	Amgen's Olpasiran May Still Show Heart-Risk Reduction Despite Novartis Miss, UBS Says	MT
09-08	Rothschild & Co Redburn Adjusts Price Target on Amgen to $225 From $235, Keeps Sell Rating	MT
09-08	BMO Capital Downgrades Amgen to Market Perform From Outperform, Price Target is $450	MT
09-08	Analyst recommendations: Amgen, Equifax, Lockheed Martin, Phillips 66, Valero Energy…
09-07	Analyst recommendations: Amgen, Broadcom, Lululemon, Palo Alto Networks…
09-04	Wells Fargo Adjusts Price Target on Amgen to $435 From $400, Keeps Equalweight Rating	MT
08-20	Piper Sandler Adjusts Price Target on Amgen to $457 From $427, Maintains Overweight Rating	MT
08-19	Argus Research Adjusts Amgen Price Target to $460 From $375, Maintains Buy Rating	MT
08-19	Morgan Stanley Adjusts Price Target on Amgen to $362 From $351, Keeps Equalweight Rating	MT
08-18	Mizuho Adjusts Price Target on Amgen to $352 From $303, Maintains Neutral Rating	MT
08-18	Cantor Fitzgerald Adjusts Price Target on Amgen to $400 From $350, Maintains Neutral Rating	MT
08-17	Mizuho Securities Adjusts Amgen Price Target to $352 From $303	MT
08-13	Daiwa Securities Adjusts Price Target on Amgen to $430 From $390, Keeps Outperform Rating	MT
08-13	Barclays Adjusts Price Target on Amgen to $380 From $360, Maintains Equalweight Rating	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELI LILLY AND COMPANY					+12.47%
	JOHNSON & JOHNSON					+6.1%
	ABBVIE INC.					+0.53%
	MERCK & CO., INC.					+9.07%
	ROCHE HOLDING AG					+4.79%
	NOVARTIS AG					+4.48%
	ASTRAZENECA PLC					+31.52%
	AMGEN INC.					-5.67%
	GILEAD SCIENCES, INC.					+6.11%
	Average					+7.71%
	Weighted average by Cap.					+8.12%